Delaware
|
000-25169
|
98-0178636
|
(State
or Other
|
(Commission
|
(IRS
Employer
|
Jurisdiction
of
|
File
Number)
|
Identification
|
Incorporation)
|
Number)
|
33
Harbour Square, Suite 202, Toronto,
Ontario Canada
|
M5J
2G2
|
(Address
of Principal Executive
Offices)
|
(Zip
Code)
|
4.1
|
Agreement
to Amend Additional Investment Right between the Company and Cranshire
Capital, L.P. dated February 28, 2006.
|
4.2
|
Agreement
to Amend Additional Investment Right between the Company and Omicron
Master Trust dated February 28, 2006.
|
4.3
|
Agreement
to Amend Additional Investment Right between the Company and Iroquois
Capital LP dated February 28, 2006.
|
4.4
|
Agreement
to Amend Additional Investment Right between the Company and Smithfield
Fiduciary LLC dated February 28, 2006.
|
GENEREX BIOTECHNOLOGY CORPORATION | ||
|
|
|
Dated: February 28, 2006 | By: | /s/ Rose Perri |
Chief Operating Officer and |
||
Chief Financial Officer | ||
(principal financial officer) |
4.1
|
Agreement
to Amend Additional Investment Right between the Company and Cranshire
Capital, L.P. dated February 28, 2006.
|
4.2
|
Agreement
to Amend Additional Investment Right between the Company and Omicron
Master Trust dated February 28, 2006.
|
4.3
|
Agreement
to Amend Additional Investment Right between the Company and Iroquois
Capital LP dated February 28, 2006.
|
4.4
|
Agreement
to Amend Additional Investment Right between the Company and Smithfield
Fiduciary LLC dated February 28, 2006.
|